Uncategorized

Campbell Soup net leverage now below peers

admin | June 5, 2020

This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors. This material does not constitute research.

CPB posted strong fiscal 3Q20 results this week fueled by pandemic pantry stocking for comfort foods that also deliver on value. Management has continued its commitment to reducing leverage via proceeds from asset sales and cash from operations, and CPB has achieved a net leverage ratio of 3.0x which is below other BBB peers that are in also in debt reduction mode post acquisitions. Notably CPB’s 10/30s curve is the flattest of its peers despite having margins close to General Mills (GIS) and better net leverage; this provides an attractive entry point into CPB 10-year bonds. Assuming the same curve differential, CPB 10-year bonds have at least 8 bp of upside from current levels.

Exhibit 1. BBB Packed Food Comps – LTM Basis

Source: Company report; Amherst Pierpont Securities

Fiscal 3Q20 Overview

The increased demand resulted in double-digit growth in both sales and operating profit. The soup business witnessed impressive growth as soup household penetration was up nearly 10 points in the quarter. CPB posted organic net sales growth of 17% in the quarter which was all fueled by volume/mix growth. Gross margin increased 100 bp year-over-year (to 34.7%) due to favorable product mix, improved operating leverage as well as supply chain improvements and cost reductions. Additionally, we note that the EBIT margin witnessed 220 bp of growth (to 17.3%), reflecting the improvement in the gross margin and higher sales volumes. CPB realized total cost savings of $30 million in the quarter and $120 million in the first nine months of fiscal 2020. To date, $680mm of enterprise cost savings and synergies from the Synder’s-Lance acquisition have been achieved. Management remains on track to hit its cumulative savings target of $850 million by FYE22.

The Meals & Beverages unit outpaced the Snacks unit in terms of sales growth for the first time in 12 quarters. Net sales in Meals & Beverages were up 21% in the quarter as growth in soups was up 35% and food purchases for at home consumption more than offset the negative impact from the foodservice business. Meals & Beverages operating earnings increased 35% primarily due to the volume gains and better gross profit performance. Snacks saw organic growth sales growth of 12% while operating earnings were up 19%. The strong Snacks performance reflected increased household penetration of 5.4%, with increases witnessed across all nine power brands. Management noted that seven out of their nine power brands held or grew market share during the quarter.

On Pace to Hit Net Leverage Target

CPB ended the quarter with net debt of roughly $5.5 billion. CPB has made significant progress in delevering the balance sheet since the close of the Synder’s-Lance acquisition. CPB’s net debt balance declined by $2.9bn in the first nine months of fiscal 2020 as the company used non-core asset sale proceeds and cash from operations to repay debt. Since the close of the acquisition in March 2018, we note that CPB has reduced net debt by $4.1 billion. While the company raised $1 billion through the issuance of 10-year and 30-year bonds in April, $300 million was used to repay borrowings under the revolver. The remaining proceeds are expected to reduce debt further, making the April transaction leverage neutral. Management noted that it ended the quarter with net leverage of 3.2x (as it excludes EBITDA from operations divested in the quarter), and they remain on pace to hit their stated 3.0x net leverage target by fiscal 2021.

Full Year Guidance Raised

With few companies providing full year guidance at this point, CPB not only provided guidance but raised its targets for the fiscal year based on 3Q performance and its outlook for continued demand for its products. As such, management is now forecasting organic net sales to be up in the 5.5%-6.5% range, which is up from previous guidance of a decline of 1% to growth of 1%. Adjusted EBIT is now expected to grow in the 12%-14% range, up from previous indications for 2%-4% growth. Adjusted EPS was raised from a range of $2.55-$2.60 to $2.87-$2.92. Fiscal 2020 is a 53-week year (resulting in an additional week) which management believes will have a 2 percentage point contribution to adjusted EBIT and EPS. The organic net sales guidance excludes this contribution as well as the negative two percentage point impact from the sale of the European chips business.

admin
jkillian@apsec.com
john.killian@santander.us 1 (646) 776-7714

This material is intended only for institutional investors and does not carry all of the independence and disclosure standards of retail debt research reports. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.

This message, including any attachments or links contained herein, is subject to important disclaimers, conditions, and disclosures regarding Electronic Communications, which you can find at https://portfolio-strategy.apsec.com/sancap-disclaimers-and-disclosures.

Important Disclaimers

Copyright © 2024 Santander US Capital Markets LLC and its affiliates (“SCM”). All rights reserved. SCM is a member of FINRA and SIPC. This material is intended for limited distribution to institutions only and is not publicly available. Any unauthorized use or disclosure is prohibited.

In making this material available, SCM (i) is not providing any advice to the recipient, including, without limitation, any advice as to investment, legal, accounting, tax and financial matters, (ii) is not acting as an advisor or fiduciary in respect of the recipient, (iii) is not making any predictions or projections and (iv) intends that any recipient to which SCM has provided this material is an “institutional investor” (as defined under applicable law and regulation, including FINRA Rule 4512 and that this material will not be disseminated, in whole or part, to any third party by the recipient.

The author of this material is an economist, desk strategist or trader. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM or any of its affiliates may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.

This material (i) has been prepared for information purposes only and does not constitute a solicitation or an offer to buy or sell any securities, related investments or other financial instruments, (ii) is neither research, a “research report” as commonly understood under the securities laws and regulations promulgated thereunder nor the product of a research department, (iii) or parts thereof may have been obtained from various sources, the reliability of which has not been verified and cannot be guaranteed by SCM, (iv) should not be reproduced or disclosed to any other person, without SCM’s prior consent and (v) is not intended for distribution in any jurisdiction in which its distribution would be prohibited.

In connection with this material, SCM (i) makes no representation or warranties as to the appropriateness or reliance for use in any transaction or as to the permissibility or legality of any financial instrument in any jurisdiction, (ii) believes the information in this material to be reliable, has not independently verified such information and makes no representation, express or implied, with regard to the accuracy or completeness of such information, (iii) accepts no responsibility or liability as to any reliance placed, or investment decision made, on the basis of such information by the recipient and (iv) does not undertake, and disclaims any duty to undertake, to update or to revise the information contained in this material.

Unless otherwise stated, the views, opinions, forecasts, valuations, or estimates contained in this material are those solely of the author, as of the date of publication of this material, and are subject to change without notice. The recipient of this material should make an independent evaluation of this information and make such other investigations as the recipient considers necessary (including obtaining independent financial advice), before transacting in any financial market or instrument discussed in or related to this material.